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We examined population-based information on relapsed childhood haematological cancers, investigating factors that might influence
both overall survival and survival following relapse among the 1177 children (0–14 years) diagnosed with a haematological
malignancy in Yorkshire from 1974 to 2003, of whom 342 (29%) relapsed at least once. Leukaemia patients from more deprived
areas were significantly less likely to relapse (odds ratio¼0.54, 95% confidence interval 0.32–0.93 for most deprived quintile vs least
deprived quintile; Ptrend¼0.06), especially those with acute myeloid leukaemia (P¼0.04). Neither ethnic group nor distance to the
main treatment centre was associated with risk of relapse. Overall, patients who relapsed at least once had 5-year survival rates of
46% (41–51%) compared with 79% (76–81%) of those who did not. Five-year survival rates from the time of first relapse increased
from 20% in 1974–1983 to 45% in 1984–2003. Length of first remission was a strong predictor of survival for leukaemia with a 46%
reduced risk of death for every additional year of event-free survival. Of children who experienced a relapse, 46% survived at least 5
years, whereas just under half of patients survived 5 years beyond disease recurrence. This provides a baseline for future comparisons
and demonstrates that relapsed childhood cancer need not imply a poor outcome.
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Population based survival rates now exceed 70% for all
malignancies diagnosed under the age of 15 in the UK (Coleman
et al, 1999), having improved steadily since 1950 (Stiller and
Bunch, 1990). Despite improved prognosis, an appreciable number
of patients still fail first-line treatment, with 75% of deaths
occurring in paediatric oncology units (Al-Asiri et al, 1992) and
among long-term survivors of childhood cancer in a population-
based series (Robertson et al, 1994) being due to recurrent disease.
In an audit of care carried out in the 1990s in a tertiary
paediatric oncology unit in Leeds (unpublished), relapsed disease
accounted for up to 50% of all inpatient bed occupancy,
constituting a major part of the unit’s workload. Most literature
on relapse concerns acute lymphoblastic leukaemia (ALL), and is
almost entirely limited to patients either on a trial protocol or
selected from a hospital-based series (Eden et al, 2000; Gustafsson
et al, 2000; Lawson et al, 2000; Schrappe et al, 2000; Silverman
et al, 2000; Tsuchida et al, 2000; Vilmer et al, 2000; Chessells et al,
2003; Roy et al, 2005), although one paper from Scandinavia has
reported on the outcome following relapse ALL in a population-
based cohort (Schroeder et al, 1995). A smaller number of studies
have focused on relapse associated with acute myeloid leukaemia
(Caspers and Creutzig, 2005; Gibson et al, 2005; Lie et al, 2005).
We examined population-based information on relapsed child-
hood haematological cancers, looking at factors that might
influence both overall survival and survival following relapse; we
also tested the local clinical impression that time to relapse was
increasing in response to more intensive treatment.
MATERIALS AND METHODS
Diagnostic, clinical and demographic information on all children
diagnosed under the age of 15 with a haematological malignancy
from 1974 to 2003 was obtained from the Yorkshire Specialist
Register of Cancer in Children and Young People, covering the
former Yorkshire Regional Health Authority (Feltbower et al,
2001). Checks with adjoining childhood cancer registries and the
National Registry of Childhood Tumours (Stiller et al, 1998) are
carried out routinely to ensure optimum ascertainment rates.
Overall, 90% of diagnoses were confirmed by histopathology,
although this proportion increased substantially over time,
averaging 98% since 1986. Children were actively followed up
every 2 years with general practitioners and hospital records to
determine their health status, treatment and any adverse outcomes
such as relapse or second malignancies. Our clinical definition of
‘relapse’ was recurrent disease, either occurring locally at the same
site as the initial diagnosis and/or elsewhere, and the date of
this event was recorded. A cross-check with the national clinical
trials database (www.ctsu.ox.ac.uk) was undertaken to ensure all
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complete.
Each patient’s diagnosis was coded with ICD-O-2/ICD-10
morphology and site codes and categorised according to the
International Classification of Childhood Cancer (ICCC) as either
leukaemia (group I) or lymphoma (group II) (Krama ´rova ´ et al,
1996). Information on the following explanatory risk factors was
derived for each patient: deprivation, ethnicity and distance from
main treating centre. The full address and postcode of each patient
at diagnosis was validated and linked to a small census area
(enumeration district, ED). The Townsend deprivation score was
assigned to each patient based on the 1991 census, including
unemployment, car ownership, housing tenure and household
overcrowding (Townsend et al, 1988) and categorised into
quintiles. The Townsend index has been shown to be a reliable
measure of an individual’s social class (Danesh et al, 1999).
Distance to treatment centre of more or less than 20km from the
main treating centre was derived by allocating a 100m grid
reference to the location of each subject’s residence (by ED
centroid) together with their treating hospital within the Yorkshire
Region. Ethnic group, defined as south Asian or not, was assigned
to each individual based on their full name according to a south
Asian names data dictionary (Nam Pehchan, City of Bradford
Metropolitan District Council, 2002) and verified using a
secondary source (London School of Hygiene and Tropical
Medicine, 1999). The Nam Pehchan software has been shown to
be a robust measure of categorising ethnic origin (Cummins et al,
1999).
The overall risk of a first relapse episode occurring was analysed
using logistic regression in relation to the following factors: age at
diagnosis, sex, period of diagnosis, deprivation, ethnic group,
entry into a randomised clinical trial and distance from residence
to the main hospital of treatment. We excluded from the regression
modelling any patients who died before reaching remission to
ensure that the nonrelapse comparison group was homogeneous.
The remission period was defined as 5 weeks postdiagnosis
following standard evaluation of patient response to induction
therapy at this time (Gaynon et al, 1997) and because most patients
will have achieved remission within this period. To compare the
risk for those who relapsed vs those who never relapsed, we report
odds ratios (OR) and 95% confidence intervals (CI). Each model’s
goodness-of-fit was assessed (Hosmer and Lemeshow, 1989). For
patients who had relapsed at least once, Cox regression was used to
assess whether the risk of death was influenced by time to first
relapse, the variables listed above or the site of first relapse (bone
marrow7other sites (BM), central nervous system (CNS), testis
and other). All patients were followed up until 31 May 2006.
RESULTS
Hosmer–Lemeshow goodness-of-fit tests showed that all the
models fitted the data well.
Relapse patterns
One thousand one hundred and seventy-seven children were
identified, 856 with leukaemia and 321 with lymphoma. Three
hundred and forty-two (29%) of these patients relapsed at least
once (Table 1). Of the 18 patients diagnosed with Burkitt
lymphoma, only two relapsed, so it was decided not to combine
non-Hodgkin’s lymphoma (NHL; ICCC group IIb) and Burkitt
lymphoma (ICCC group IIc) together in the statistical analysis.
Children with lymphoma were significantly less likely to relapse
(20%) than those with leukaemia (32%): OR¼0.53 (95% CI 0.39–
0.72). Median time to relapse showed some differences: patients
with ALL and Hodgkin’s lymphoma relapsed after 2.2 years (range
1 month to 18 years), whereas those with acute myeloid leukaemia
(AML), ‘other’ leukaemia (ICCC groups Ic–Ie), NHL and ‘other’
lymphoma (ICCC groups IIc–IIe) relapsed after 0.7–1.5 years
(range 1 month to 24 years). There was no variation in time to first
relapse by diagnostic period.
Factors associated with relapsed disease
Of the 200 individuals who died but never relapsed, 77 did so
within 5 weeks of their diagnosis date and were excluded from
the logistic regression modelling: these mainly consisted of ALL
(n¼27), AML (n¼26) and NHL (n¼15).
Leukaemia
Females with ALL were significantly less likely to relapse than
males (OR¼0.69; 95% CI 0.51–0.95), with AML displaying a
similar but nonsignificant association (OR¼0.43; 95% CI 0.18–
1.01). Older children (ages 10–14) with leukaemia had a slightly
higher risk of relapse compared with 0–4 year old children
(OR¼1.41; 95% CI 0.94–2.11), although this effect was not
significant for any diagnostic subgroup.
Children diagnosed with leukaemia in 1984–1993 and 1994–
2003 were significantly less likely to relapse than those diagnosed
in 1974–1983 (Ptrend¼0.01). This effect was not entirely explained
by reduced rates of early relapse: for example, the proportion of
children who relapsed 3 years postdiagnosis decreased over time
from 16% in 1974–1983 to 6% in 1994–2003. Patients entered into
Table 1 Proportion of childhood (0–14 years) haematological patients having relapsed according to survival status, diagnosed between 1974–2003 in
Yorkshire, UK
Patients alive at 31 May 2006 Deceased patients All registered patients
ICCC
a
Ever relapsed Ever relapsed Ever relapsed
group Diagnostic group Yes (%) No (%) Yes (%) No (%) Yes (%) No (%) Total
I Leukaemia 78 (15.2%) 435 (84.8%) 199 (58.0%) 144 (42.0%) 277 (32.4%) 579 (67.6%) 856
Ia Acute lymphoid leukaemia 66 (15.0%) 375 (85.0%) 162 (69.8%) 70 (30.2%) 228 (33.9%) 445 (66.1%) 673
Ib Acute myeloid leukaemia 12 (20.7%) 46 (79.3%) 31 (34.4%) 59 (65.6%) 43 (29.1%) 105 (70.9%) 148
Ic–e Other leukaemia
b 0 (0.0%) 14 (100.0%) 6 (28.6%) 15 (71.4%) 6 (17.1%) 29 (82.9%) 35
II Lymphoma 27 (11.9%) 200 (88.1%) 38 (40.4%) 56 (59.6%) 65 (20.2%) 256 (79.8%) 321
IIa Hodgkin’s lymphoma 16 (13.3%) 104 (86.7%) 5 (33.3%) 10 (66.7%) 21 (15.6%) 114 (84.4%) 135
IIb Non-Hodgkin’s lymphoma 10 (13.5%) 64 (86.5%) 26 (43.3%) 34 (56.7%) 36 (26.9%) 98 (73.1%) 134
IIc–e Other lymphoma
b 1 (3.0%) 32 (97.0%) 7 (36.8%) 12 (63.2%) 8 (15.4%) 44 (84.6%) 52
Total 105 (14.2%) 635 (85.8%) 237 (54.2%) 200 (45.8%) 342 (29.1%) 835 (70.9%) 1177
aICCC: International Classification of Childhood Cancer (Krama ´rova ´ et al, 1996).
bExcluded from main analyses.
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who were not.
Children in the most deprived areas had a significantly lower
risk of relapse than those from the most affluent areas
(Ptrend¼0.06; OR¼0.54, 95% CI 0.32–0.93 for most deprived
quintile vs least deprived quintile). This effect was most marked
for those with AML (Ptrend¼0.04). No significant differences in
risk of relapse were evident according to ethnic group or distance
to the main treatment centre.
Lymphoma
No significant differences by gender were observed for lymphoma.
The general pattern of a lower risk of relapse for those diagnosed
more recently was observed, especially for NHL, although no
significant trends were found. Trial entry was associated with a
significant reduction in risk of relapse, although no consistent
associations were seen with deprivation. Neither ethnic group nor
distance to treatment centre influenced the risk of relapse.
Factors associated with survival following relapse
Median survival times for leukaemia and lymphoma following the
first relapse were 1.5 and 1.15 years, respectively. Overall, patients
who relapsed at least once had 5-year survival rates from diagnosis
of 46% (95% CI 41–51%) compared with 79% (76–81%) for those
who never relapsed. Results were similar for other diagnostic
groups except AML, where 5-year survival rates were 30 and 46%
for relapsed and nonrelapsed diseases, respectively. Survival rates
for leukaemia from the time of first relapse (Figure 1) showed that
only 20% of patients survived beyond 5 years if diagnosed in
1974–1983 compared with 45% if diagnosed in 1984–2003
(Ptrend¼0.01). Patients with AML showed an even more dramatic
improvement in 5-year survival rates, rising from 0% in 1974–
1983 to 35% in 1984–1993 and 53% in 1994–2003.
Table 2 presents the hazard ratio (HR) estimates and 95% CI
derived from the Cox regression analysis for the 342 patients who
experienced at least one relapse episode. Results for ‘other’
leukaemia (ICCC groups Ic–e), Hodgkin’s lymphoma (IIa), NHL
(IIb) and ‘other’ lymphoma (IIc–e) are not shown because of small
numbers.
Leukaemia
Females had a nonsignificantly increased risk of death compared
with males for leukaemia (HR¼1.32, 95% CI 0.96–1.82) and all
other diagnostic subgroups. A significantly increased risk of death
was observed for 10–14-year-olds with leukaemia compared with
those aged 0–4 years (HR¼1.53, 95% CI 1.05–2.23).
For both ALL and AML, individuals diagnosed in the two most
recent decades were significantly less likely to die than those
diagnosed in 1974–1983 (Ptrend¼0.001). No significant differences
in survival were found by ethnic group, although patients treated
on a trial protocol had a nonsignificantly reduced risk of death.
Increasing levels of deprivation were associated with an increased
risk of death for leukaemia, but no significant trends were
observed for any subgroup. Time to first relapse was strongly
associated with length of survival for all diagnostic subgroups: for
all leukaemia combined, patients were 46% less likely to die for
every additional year of event-free survival (HR¼0.54, 95% CI
0.47–0.62). Site of relapse had a significant impact on survival for
ALL: testis and CNS relapses had significantly higher survival rates
compared with BM. Distance to the main treatment centre did not
influence survival.
Lymphoma
No significant difference in survival was observed for lymphoma
patients by gender, age, period of diagnosis, ethnicity or distance
to the main treatment centre. Trial entry did not show any
beneficial effect on survival, revealing a slightly elevated risk of
death. No significant trends across deprivation quintiles were
observed, although individuals from the least deprived areas were
least likely to die. Time to first relapse had an impact on survival,
albeit less pronounced than that for leukaemia (HR¼0.87, 95% CI
0.74–1.02). No significant differences in survival were observed by
site of relapse.
DISCUSSION
We report for the first time factors influencing the risk of relapsed
childhood haematological cancer from a UK cohort spanning
30 years, together with their subsequent survival chances. Our
findings indicate that 30% of leukaemia and 20% of lymphoma
patients are likely to relapse at least once. Time to first relapse was
similar for ALL and Hodgkin’s lymphoma, although somewhat
shorter for AML, other leukaemia subtypes and NHL, but accorded
with previous ALL reports (Gustafsson et al, 1987, 2000; Eden et al,
2000; Lawson et al, 2000; Schrappe et al, 2000; Silverman et al,
2000; Tsuchida et al, 2000; Vilmer et al, 2000; Chessells et al, 2003;
Roy et al, 2005). There was no change in the median time to
relapse for any diagnostic group across the study period, which
therefore did not confirm local impressions that more children
were surviving longer at the expense of more frequent relapses.
A key finding was the 46% 5-year survival rates for those who
had relapsed, in contrast to 79% for those who did not relapse.
This observation was seen across all diagnostic groups except
AML and is consistent with recent international and UK data on
ALL (Schroeder et al, 1995; Chessells, 1998; Lawson et al, 2000;
Chessells et al, 2003; Roy et al, 2005), although our population-
based study, as well as other diagnostic groups, included a longer
follow-up period. Furthermore, almost half (45%) of leukaemia
and lymphoma patients diagnosed since 1984 survived 5 years
after their initial relapse episode, a striking improvement from the
one in five (20%) 5-year survivors diagnosed in 1974–1983.
Recurrent disease therefore need not imply a poor outcome for
childhood haematological cancer.
Time to first relapse was an important prognostic indicator,
in agreement with other international and UK findings for ALL
(Schroeder et al, 1995; Chessells, 1998; Lawson et al, 2000;
Chessells et al, 2003; Roy et al, 2005), our data indicating a 46%
improvement in survival for leukaemia for every year of event-free
survival since diagnosis. Localisation of relapse was also a
significant prognostic factor for ALL, with testis and CNS relapses
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Figure 1 Postrelapse survival trends by period of diagnosis for childhood
leukaemia diagnosed between 1974 and 2003 in Yorkshire, UK.
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survival following relapse was observed for leukaemia patients
entered into a clinical trial and for those diagnosed more recently.
Five-year overall survival rates of 45% for patients who had
relapsed in our Yorkshire cohort diagnosed in the 1990s is only
marginally lower than data reported from UK ALL R1 and R2 trials
showing 56% overall survival during the same period (Lawson
et al, 2000; Roy et al, 2005). Equivalent postrelapse survival rates
for AML showed a consistent improvement over the study period
from 0% in 1974–1983 up to 53% in 1994–2003. This correlates
well with a general trend in the reduction of the cumulative risk of
relapse for patients on trials (Caspers and Creutzig, 2005; Lie et al,
2005) and agrees with 5-year post-relapse survival rates of around
30% reported from other UK data between 1988 and 1995 (Gibson
et al, 2005). Females who had relapsed had a slightly (but not
significantly) greater risk of death than males, in contrast to the
usual finding that females survive longer than males for most
diagnostic groups (Coleman et al, 1999); this requires confirma-
tion in other populations.
Leukaemia patients from more deprived areas were significantly
less likely to relapse initially than those from the most affluent
areas, although this effect was largely restricted to AML. This novel
finding is rather puzzling, as it is unlikely to be due to lack of
access to treatment as most young children visit tertiary referral
centres both for their main therapy and long-term follow-up;
moreover, distance to treatment centre was not associated with
risk of relapse. Nor could it be explained by any variation in
fatality rate before reaching remission by level of deprivation. For
those patients with complete stage of tumour recorded, more
aggressive cancers were not related to deprivation category. Given
the relatively small numbers who had relapsed with leukaemia, the
associations with deprivation may be due to chance.
Females with leukaemia were less likely to relapse than males, as
were younger patients, supporting previous UK findings for ALL
(Lawson et al, 2000). Those diagnosed during the earliest decade
(1974–1983) had the poorest prognosis irrespective of leukaemia
subtype. NHL followed the same patterns as leukaemia in terms of
the effect on relapse from sex and period of diagnosis, whereas
Hodgkin’s lymphoma exhibited a nonsignificantly higher risk for
female patients, and only those diagnosed in the most recent
decade (1994–2003) had a reduced risk of relapse compared to
earlier registrations.
Table 2 Cox regression: association between risk factors and survival following relapsed childhood haematological cancer diagnosed between 1974–
2003 in Yorkshire, UK
Leukaemia (ICCC Ia–e) ALL (ICCC
a Ia) AML (ICCC
a Ib) Lymphoma (ICCC
a IIa–e)
Factor HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Sex
Males 1.00 1.00 1.00 1.00
Females 1.32 0.96–1.82 1.20 0.82–1.75 2.06 0.65–6.55 1.06 0.43–2.59
Age group
0–4 1.00 1.00 1.00 1.00
5–9 0.98 0.69–1.40 0.88 0.59–1.30 3.16 0.46–21.37 1.48 0.50–4.39
10–14 1.53 1.05–2.23 1.33 0.86–1.07 2.59 0.84–7.99 1.22 0.41–3.61
Period of diagnosis
1974–1983 1.00 1.00 1.00 1.00
1984–1993 0.55 0.38–0.79 0.59 0.39–0.88 0.95 0.26–3.51 1.36 0.45–4.10
1994–2003 0.39 0.26–0.61 0.43 0.27–0.69 0.19 0.04–0.84 2.28 0.71–7.29
Entered clinical trial
No 1.00 1.00 1.00 1.00
Yes 0.74 0.52–1.07 0.77 0.49–1.22 1.76 0.40–7.67 1.16 0.49–2.73
Ethnic group
Non-south Asian 1.00 1.00 1.00 1.00
South Asian 0.85 0.45–1.62 1.06 0.49–2.29 0.22 0.02–2.87 1.20 0.36–3.95
Deprivation
I (lowest) 1.00 1.00 1.00 1.00
II 1.26 0.79–2.00 1.43 0.86–2.36 0.51 0.09–2.99 4.87 1.18–20.06
III 0.97 0.61–1.54 0.87 0.52–1.48 2.48 0.45–13.71 3.98 1.06–14.92
IV 1.25 0.79–1.98 0.99 0.59–1.66 1.68 0.33–8.54 1.48 0.44–5.01
V (highest) 1.71 1.03–2.84 1.62 0.92–2.86 0.46 0.07–3.01 2.15 0.59–7.78
Ptrend¼0.11 Ptrend¼0.57 Ptrend¼0.92 Ptrend¼0.50
Time to 1st relapse (years) 0.54 0.47–0.62 0.54 0.46–0.64 0.47 0.23–0.97 0.87 0.74–1.02
Distance to treatment hospital: o20km 1.00 1.00 1.00 1.00
X20km 1.17 0.84–1.64 1.04 0.71–1.53 1.07 0.33–3.45 1.28 0.53–3.06
Site of relapse
Bone marrow 1.00 1.00 1.00 1.00
Testis 0.43 0.24–0.75 0.35 0.19–0.63 — — 0.91 0.09–9.59
Central Nervous system 0.42 0.24–0.72 0.50 0.28–0.89 — — 0.35 0.06–2.03
Other 0.86 0.50–1.48 0.79 0.43–1.44 0.62 0.06–6.02 0.60 0.22–1.65
ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CI, confidence interval; HR, hazard ratio;
aICCC: International Classification of Childhood Cancer (Krama ´rova ´
et al, 1996)
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the number of relapses observed within each diagnostic group (eg
277 out of 856 for leukaemia) and secondly by the number of
deaths experienced. This precluded more detailed investigations of
relapse patterns and survival trends. Also, some patients diagnosed
in the most recent period will have not experienced relapsed
disease due to censoring, although analyses took this into account.
Details of biological markers and molecular genetics were not
uniformly available for the Yorkshire cohort. However, biological
information can be a useful tool for indicating survival chances
following relapse. For instance, for relapsed ALL, the presence of
11q23 abnormalities and Ph
1-positive ALL may be linked with a
poorer prognosis (Vora et al, 1996; Chessells et al, 2003) whereas
survivors with the TEL-AML 1 fusion transcript had an extended
second remission period compared with those without (Seeger
et al, 1997). Differences in the molecular characteristics of tumours
occurring across deprivation quintiles may partly explain some of
our findings.
The observation that almost half of all patients with any
haematological malignancy (except AML) registered since 1974
who fail first-line treatment and relapse survive 5 years beyond
their diagnosis and the same proportion survive 5 years beyond
their initial relapse episode is an important finding as it has been
achieved without an increase in the number of long-term relapse
episodes: it provides a baseline figure for future studies. Links
between deprivation and the risk of relapse and subsequent
survival require validation in other population-based cohorts.
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